ATE459883T1 - Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose - Google Patents
Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnoseInfo
- Publication number
- ATE459883T1 ATE459883T1 AT05715950T AT05715950T ATE459883T1 AT E459883 T1 ATE459883 T1 AT E459883T1 AT 05715950 T AT05715950 T AT 05715950T AT 05715950 T AT05715950 T AT 05715950T AT E459883 T1 ATE459883 T1 AT E459883T1
- Authority
- AT
- Austria
- Prior art keywords
- diagnosis
- cancer prognosis
- proliferation markers
- clinical practice
- new proliferation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000004393 prognosis Methods 0.000 title abstract 2
- 230000035755 proliferation Effects 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 102000008868 Chromatin Assembly Factor-1 Human genes 0.000 abstract 2
- 108010088529 Chromatin Assembly Factor-1 Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54811104P | 2004-02-27 | 2004-02-27 | |
| PCT/EP2005/002578 WO2005085860A2 (en) | 2004-02-27 | 2005-02-28 | New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE459883T1 true ATE459883T1 (de) | 2010-03-15 |
Family
ID=34919336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05715950T ATE459883T1 (de) | 2004-02-27 | 2005-02-28 | Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7781174B2 (de) |
| EP (1) | EP1721165B1 (de) |
| JP (1) | JP4848355B2 (de) |
| AT (1) | ATE459883T1 (de) |
| CA (1) | CA2555656C (de) |
| DE (1) | DE602005019694D1 (de) |
| WO (1) | WO2005085860A2 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11254916B2 (en) | 2006-03-02 | 2022-02-22 | Viacyte, Inc. | Methods of making and using PDX1-positive pancreatic endoderm cells |
| DK2650360T3 (da) | 2006-03-02 | 2019-10-07 | Viacyte Inc | Endokrine prekursorceller, pancreatiske hormon udtrykkende celler og fremgangsmåder til fremstilling |
| US20100144830A1 (en) * | 2006-09-19 | 2010-06-10 | Masahiko Kuroda | Cancer cell identification marker and cancer cell proliferation inhibitor |
| CA2687747C (en) | 2007-05-30 | 2015-11-17 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
| WO2009126543A1 (en) | 2008-04-08 | 2009-10-15 | Nuclea Biomarkers, Llc | Biomarker panel for prediction of recurrent colorectal cancer |
| EP2243843A1 (de) * | 2009-04-24 | 2010-10-27 | Institut Curie | HP1-Alpha als prognostischer Marker bei Krebserkrankungen des Menschen |
| WO2011151321A1 (en) | 2010-05-31 | 2011-12-08 | Institut Curie | Asf1b as a prognosis marker and therapeutic target in human cancer |
| JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 |
| WO2016198833A2 (en) | 2015-06-08 | 2016-12-15 | Arquer Diagnostics Limited | Methods |
| EP4060344A1 (de) | 2015-06-08 | 2022-09-21 | Arquer Diagnostics Limited | Verfahren und kits |
| US10839509B2 (en) | 2015-07-10 | 2020-11-17 | 3Scan Inc. | Spatial multiplexing of histological stains |
| WO2018183603A1 (en) * | 2017-03-30 | 2018-10-04 | The Board Of Trustees Of The University Of Illinois | Method and kit for diagnosing early stage pancreatic cancer |
| JP7025730B2 (ja) | 2018-02-28 | 2022-02-25 | 日東紡績株式会社 | 固定化細胞又はｆｆｐｅ組織切片から抗原性を増強した細胞核を脱離する方法並びにそのための抗原賦活剤及びキット |
| CN111766385B (zh) * | 2020-07-06 | 2023-09-26 | 河南赛诺特生物技术有限公司 | 术中快速鉴别肺癌和硬化性肺细胞瘤的免疫组化试剂盒 |
| CN113984483B (zh) * | 2021-09-28 | 2023-10-20 | 福建医科大学 | 一种冰冻切片盖玻片贴片染色方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6071715A (en) * | 1993-08-12 | 2000-06-06 | Board Of Regents, The University Of Texas System | Nucleic acids encoding novel proteins which bind to retinoblastoma protein |
| EP1336660A4 (de) * | 2000-11-24 | 2006-03-15 | Eisai Co Ltd | Testverfahren für die empfindlichkeit von tumorzellen gegenüber antikrebsmitteln |
| AU2002330039A1 (en) * | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
| WO2003073911A2 (en) * | 2002-02-28 | 2003-09-12 | Georgetown University | Method and composition for detection and treatment of breast cancer |
-
2005
- 2005-02-28 CA CA2555656A patent/CA2555656C/en not_active Expired - Fee Related
- 2005-02-28 DE DE602005019694T patent/DE602005019694D1/de not_active Expired - Lifetime
- 2005-02-28 WO PCT/EP2005/002578 patent/WO2005085860A2/en not_active Ceased
- 2005-02-28 EP EP05715950A patent/EP1721165B1/de not_active Expired - Lifetime
- 2005-02-28 JP JP2007500191A patent/JP4848355B2/ja not_active Expired - Fee Related
- 2005-02-28 AT AT05715950T patent/ATE459883T1/de not_active IP Right Cessation
-
2006
- 2006-08-28 US US11/510,612 patent/US7781174B2/en not_active Expired - Fee Related
-
2010
- 2010-06-03 US US12/792,855 patent/US20110003706A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20110003706A1 (en) | 2011-01-06 |
| CA2555656C (en) | 2017-03-28 |
| WO2005085860A3 (en) | 2005-11-10 |
| EP1721165A2 (de) | 2006-11-15 |
| US7781174B2 (en) | 2010-08-24 |
| US20070077577A1 (en) | 2007-04-05 |
| DE602005019694D1 (de) | 2010-04-15 |
| JP4848355B2 (ja) | 2011-12-28 |
| JP2007524103A (ja) | 2007-08-23 |
| EP1721165B1 (de) | 2010-03-03 |
| CA2555656A1 (en) | 2005-09-15 |
| WO2005085860A2 (en) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE459883T1 (de) | Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose | |
| WO2008091814A3 (en) | Assessment of asthma and allergen-dependent gene expression | |
| DK1666052T3 (da) | Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer | |
| ATE490465T1 (de) | Diagnose- und prognoseverfahren von blasenkrebs. | |
| AU2007255110A8 (en) | Circulating tumor cell assay | |
| WO2007092433A3 (en) | Osteoporosis associated markers and methods of use thereof | |
| BR112013006764A2 (pt) | método para avaliar um paciente, kit, meio legível por computador, método para avaliar um tratamento, método para avaliar o risco de um paciente, método para monitorar, método de diagnosticar, sistema de teste, método para classificar ou agrupar uma população de indivíduos, método para avaliar um desfecho substituto, método para tratar, uso de pelo menos um biomarcador, uso de um agente | |
| WO2008109414A3 (en) | Use of endogenous fluorescence to identify invading metastatic breast tumor cells | |
| NO20074817L (no) | Epidermal vekstfaktorreseptor genkopiantall | |
| NZ578283A (en) | Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring | |
| WO2006065943A3 (en) | In-vivo monitoring of circulating apoptotic cells | |
| WO2010118166A3 (en) | Methods of predicting cancer risk using gene expression in premalignant tissue | |
| MX2020002122A (es) | Sustancias de control de calidad para uso con analizadores de sedimentos en orina basados en microscopia, y metodos de uso. | |
| BR0317394A (pt) | Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal | |
| ATE430936T1 (de) | Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome | |
| EP3894868A4 (de) | Kombinatorische zeitliche biomarker und präzisionsarzneimittel mit detektions- und behandlungsmethoden zur verwendung bei nervenläsionen, nervenerkrankungen und nervenreparaturen | |
| ATE479898T1 (de) | Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs | |
| ATE545867T1 (de) | I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom | |
| WO2013072584A3 (fr) | Méthode de caractérisation de cellules tumorales circulantes et application au diagnostic | |
| PE20120592A1 (es) | Metodo con biomarcadores para el seguimiento de un tratamiento | |
| ATE512146T1 (de) | Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen | |
| ATE414701T1 (de) | Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren | |
| ATE468535T1 (de) | Verwendung von nnmt als marker für lungenkrebs | |
| DE602004022632D1 (de) | Verwendung von adiponectin zur diagnose von krebs | |
| WO2014146035A3 (en) | Compositions and methods for cancer diagnosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |